Real case studies illustrating the impact of modeling
These case studies are derived from modeling projects conducted by PhinC for biotech and pharmaceutical companies, across various stages of development.
- The molecule and its development context
- The client’s scientific or clinical challenge
- The approach implemented by PhinC (PopPK, PK/PD, PBPK…)
- The concrete contribution of modeling: informed decision-making, dose strategy, optimized study design, regulatory justification, etc.
Advance your DDI strategy with PhinC’s PBPK expertise
Whether you are preparing a First-in-Human study, assessing enzyme and transporter liabilities, or building a regulatory-ready DDI strategy, PhinC’s PBPK methodology and Standard Library provide the mechanistic insight needed for confident decision-making.
See how our approach drives measurable impact
PBPK • DDI
DDI Prediction using pre-clinical data only
The sponsor required early human DDI risk assessment to confidently support FIH dose selection and clinical planning.
PBPK • DDI
DDI exploration for a drug with complex pharmacokinetics
The sponsor needed a mechanistic understanding of DDIs in order to anticipate clinical risk and guide further development.
PBPK • DDI
Mechanism identification of complex DDI using PBPK
The sponsor was to characterize complex drug interactions (DDIs) involving multiple co-administered drugs.
PBPK • DDI
Network interaction PBPK modeling for complex victim-perpetrator DDIs
A development program aimed at accurately predicting drug interactions (DDIs) for a molecule "X".
PBPK • DDI
PBPK model development and comprehensive DDI assessment of oral solution
The sponsor required a robust, regulatory-ready PBPK model to support DDI risk assessment.
PBPK • FIH
PBPK Modeling using pre-clinical data for First-in-Human (FIH) translation
A development program required a reliable First-in-Human (FIH) dose prediction based solely on preclinical pharmacokinetic data.
Transform your clinical data into decisions with the PopPK approach
Whether you aim to understand interindividual variability, identify clinically relevant covariates, or optimize dose selection for your Phase II/III studies, PhinC’s PopPK approach delivers the quantitative insight needed for robust, regulator-aligned decisions.
See how our approach drives measurable impact
PopPK
An iterative, Population PK approach to inform Dosing Strategy in Human African Trypanosomiasis (HAT)
Definition of an optimal IMP dosing regimen and an effective PK sampling strategy for adults with human African trypanosomiasis (HAT)
PopPK
Population PK Modeling to Inform Pediatric Dosing in Human African Trypanosomiasis (HAT) during Phase III
The sponsor requested the development of a complete PopPK model based on a pediatric population with HAT (Phase III).
Download our case studies
Fill the form to receive an email with the download link.